Zobrazeno 1 - 10
of 291
pro vyhledávání: '"Adam D. Cohen"'
Autor:
Sundar Jagannath, Nedra Joseph, Concetta Crivera, Akshay Kharat, Carolyn C. Jackson, Satish Valluri, Patricia Cost, Hilary Phelps, Rafal Slowik, Timothy Klein, Lee Smolen, Xueting Yu, Adam D. Cohen
Publikováno v:
Oncology and Therapy, Vol 11, Iss 2, Pp 263-275 (2023)
Abstract Introduction Ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor T-cell (CAR-T) immunotherapy. It is indicated for treatment for adult patients with relaps
Externí odkaz:
https://doaj.org/article/ac25c55cc6c14ce2a868c9a66e746631
Multiple airway plasmacytomas: A rare cause of proximal airway obstruction requiring tumor debulking
Autor:
Christopher Ghiathi, Ashley N. Barlev, Gabriel C. Caponetti, John P. Plastaras, Devraj Basu, Adam D. Cohen, Kevin C. Ma
Publikováno v:
Clinical Case Reports, Vol 11, Iss 11, Pp n/a-n/a (2023)
Key Clinical Message Extramedullary plasmacytomas (EMP) can present as airway lesions causing central airway obstruction. Though typically solitary, EMPs should be considered in the evaluation of multifocal tracheobronchial tumors. Bronchoscopic tumo
Externí odkaz:
https://doaj.org/article/eee07fe96b79404dbb45fd7690746225
Autor:
Adam D. Cohen, Samir Parekh, Bianca D. Santomasso, Jaime Gállego Pérez-Larraya, Niels W. C. J. van de Donk, Bertrand Arnulf, Maria-Victoria Mateos, Nikoletta Lendvai, Carolyn C. Jackson, Kevin C. De Braganca, Jordan M. Schecter, Loreta Marquez, Erin Lee, Ingrid Cornax, Enrique Zudaire, Claire Li, Yunsi Olyslager, Deepu Madduri, Helen Varsos, Lida Pacaud, Muhammad Akram, Dong Geng, Andrzej Jakubowiak, Hermann Einsele, Sundar Jagannath
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 2, Pp 1-9 (2022)
Abstract Chimeric antigen receptor (CAR) T-cell therapies are highly effective for multiple myeloma (MM) but their impressive efficacy is associated with treatment-related neurotoxicities in some patients. In CARTITUDE-1, 5% of patients with MM repor
Externí odkaz:
https://doaj.org/article/c52ccfe861b6431796f476020b355a8d
Autor:
Daniel Hirschhorn, Allison Betof Warner, Rachana Maniyar, Andrew Chow, Levi M.B. Mangarin, Adam D. Cohen, Linda Hamadene, Gabrielle A. Rizzuto, Sadna Budhu, Nathan Suek, Cailian Liu, Alan N. Houghton, Taha Merghoub, Jedd D. Wolchok
Publikováno v:
JCI Insight, Vol 6, Iss 20 (2021)
Only a subset of cancer patients responds to checkpoint blockade inhibition in the clinic. Strategies to overcome resistance are promising areas of investigation. Targeting glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR
Externí odkaz:
https://doaj.org/article/e630bf7834ce472b9967dd8f1a880b48
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Multiple myeloma (MM) is a bone marrow plasma cell neoplasm and is the second most-common hematologic malignancy. Despite advances in therapy, MM remains largely incurable. Elotuzumab is a humanized IgG1 monoclonal antibody targeting SLAMF7, which is
Externí odkaz:
https://doaj.org/article/3dc2d5265821438e8c59c0cc76ab2769
Autor:
Tatiana Pazina, Alexander W. MacFarlane, Luca Bernabei, Essel Dulaimi, Rebecca Kotcher, Clinton Yam, Natalie A. Bezman, Michael D. Robbins, Eric A. Ross, Kerry S. Campbell, Adam D. Cohen
Publikováno v:
Cancers, Vol 13, Iss 2, p 226 (2021)
Accumulating evidence demonstrates important roles for natural killer (NK) cells in controlling multiple myeloma (MM). A prospective flow cytometry-based analysis of NK cells in the blood and bone marrow (BM) of MM patient subgroups was performed (sm
Externí odkaz:
https://doaj.org/article/75c17649fb994e4e897d1070881ddcda
Autor:
Tatiana Pazina, Ashley M. James, Alexander W. MacFarlane, Natalie A. Bezman, Karla A. Henning, Christine Bee, Robert F. Graziano, Michael D. Robbins, Adam D. Cohen, Kerry S. Campbell
Publikováno v:
OncoImmunology, Vol 6, Iss 9 (2017)
Elotuzumab is a humanized therapeutic monoclonal antibody directed to the surface glycoprotein SLAMF7 (CS1, CRACC, CD319), which is highly expressed on multiple myeloma (MM) tumor cells. Improved clinical outcomes have been observed following treatme
Externí odkaz:
https://doaj.org/article/e05a7c7070914bb0ac2df82d3517c889
Autor:
Alexander W. MacFarlane, Mowafaq Jillab, Mitchell R. Smith, R. Katherine Alpaugh, Marion E. Cole, Samuel Litwin, Michael M. Millenson, Tahseen Al-Saleem, Adam D. Cohen, Kerry S. Campbell
Publikováno v:
OncoImmunology, Vol 6, Iss 7 (2017)
A prospective analysis of natural killer (NK) cell phenotype and function was performed on fresh peripheral blood samples from untreated patients with B-cell chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Compared to healthy
Externí odkaz:
https://doaj.org/article/88a0d9c84d12467e99493b7558fedcd3
Publikováno v:
Frontiers in Immunology, Vol 4 (2013)
Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells through targeted cytotoxicity and further assisting in the immune response by releasing inflammatory cytokines. NK cells are th
Externí odkaz:
https://doaj.org/article/52c9ee0885e44df3b4e5a4c1c73e08ea
Autor:
Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath
Publikováno v:
Journal of Clinical Oncology. 41:1265-1274
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months. He